Table 7 Association between NuclErbB-2 expression and clinicopathological characteristics in breast cancer
From: Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
Total cohort (N = 273) | MembErbB-2+ N = 40 | MembErbB-2+/ER-PR- (N = 21) | MembErbB-2-/ER+PR+ (N = 145) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NuclErbB-2, n (%) | P value | NuclErbB-2, n (%) | P value | NuclErbB-2, n (%) | P value | NuclErbB-2, n (%) | P value | |||||
Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | |||||
Tumor size | ||||||||||||
≤ 20 mm | 46 (26.3) | 13 (13.3) | 0.012a | 4 (14.8) | 2 (16.7) | 0.885b | 2 (14.3) | 1 (14.3) | 1b | 25 (31.6) | 9 (13.8) | 0.012a |
> 20 mm | 129 (73.7) | 85 (86.7) | 23 (85.2) | 10 (83.3) | 12 (85.7) | 6 (85.7) | 54 (68.4) | 56 (86.2) | ||||
Total N (%) | 175 (64.0) | 98 (36.0) | 27 (69.2) | 12 (30.8) | 14 (66.7) | 7 (33.3) | 79 (54.9) | 65 (45.1) | ||||
Nodal metastasis | ||||||||||||
Negative | 82 (46.9) | 33 (33.7) | 0.034a | 10 (35.7) | 4 (33.3) | 0.885b | 7 (50.0) | 2 (28.6) | 0.642b | 45 (57.0) | 24 (36.4) | 0.013a |
Positive | 93 (53.1) | 65 (66.3) | 18 (64.3) | 8 (66.7) | 7 (50.0) | 5 (71.4) | 34 (43.0) | 42 (63.6) | ||||
Total N (%) | 175 (64.0) | 98 (36.0) | 28 (70.0) | 12 (30.0) | 14 (66.7) | 7 (33.3) | 79 (54.5) | 66 (45.5) | ||||
Distant metastasis | ||||||||||||
M0 | 167 (95.4) | 89 (90.8) | 0.130a | 27 (96.4) | 9 (75.0) | 0.049b | 14 (100) | 7 (100) | 75 (94.9) | 62 (93.9) | 1b | |
M1 | 8 (4.6) | 9 (9.2) | 1 (3.6) | 3 (25.5) | - | - | 4 (5.1) | 4 (6.1) | ||||
Total N (%) | 175 (64.0) | 98 (36.0) | 28 (70.0) | 12 (30.0) | 14 (66.7) | 7 (33.3) | 79 (54.5) | 66 (45.5) | ||||
Clinical stage | ||||||||||||
I | 31 (17.7) | 8 (8.2) | 0.031a | 4 (14.3) | 2 (20.0) | 0.847b | 2 (14.3) | 1 (14.3) | 1b | 18 (22.8) | 4 (6.1) | 0.005b |
II+III+IV | 144 (82.3) | 90 (91.8) | 24 (85.7) | 8 (80.0) | 12 (85.7) | 6 (85.7) | 61 (77.2) | 62 (93.9) | ||||
Total N (%) | 175 (64.0) | 98 (36.0) | 28 (73.7) | 10 (26.3) | 14 (66.7) | 7 (33.3) | 79 (54.5) | 66 (45.5) | ||||
Tumor grade | ||||||||||||
Well to moderately differentiatedc | 121 (70.3) | 57 (61.3) | 0.134a | 16 (59.2) | 5 (45.5) | 0.438a | 9 (64.3) | 3 (42.9) | 0.397b | 65 (83.3) | 42 (68.9) | 0.044a |
Poorly differentiated | 51 (29.7) | 36 (38.7) | 11 (40.8) | 6 (54.5) | 5 (35.7) | 4 (57.1) | 13 (16.7) | 19 (31.1) | ||||
Total N (%) | 172 (65.0) | 93 (35.0) | 27 (71.0) | 11 (29.0) | 14 (66.7) | 7 (33.3) | 78 (56.1) | 61 (43.9) | ||||
ERd expression | ||||||||||||
Negative | 53 (30.6) | 26 (26.8) | 0.540a | 14 (51.9) | 8 (72.7) | 0.296b | 14 (100) | 7 (100) | 1 (1.3) | 2 (3.0) | 0.457b | |
Positive | 120 (69.4) | 71 (73.2) | 13 (48.1) | 3 (27.3) | - | - | 78 (98.7) | 64 (97.0) | ||||
Total N | 173 (64.0) | 97 (36.0) | 27 (71.0) | 11 (29.0) | 14 (66.7) | 7 (33.3) | 79 (54.5) | 66 (45.5) | ||||
PRe expression | ||||||||||||
Negative | 82 (47.4) | 43 (44.8) | 0.681a | 18 (67.7) | 9 (81.8) | 0.452b | 14 (100) | 7 (100) | 15 (19.0) | 14 (21.2) | 0.739a | |
Positive | 91 (52.6) | 54 (55.2) | 9 (33.3) | 2 (18.2) | - | - | 64 (81.0) | 52 (78.8) | ||||
Total N | 173 (64.0) | 97 (36.0) | 27 (71.0) | 11 (29.0) | 14 (66.7) | 7(33.3) | 79 (54.5) | 66 (45.5) | ||||